The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S36-S41 , September 2007

Taxane Refractory Prostate Cancer

  • Paul Mathew

      Affiliations

    • M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Robert DiPaola

      Affiliations

    • University of Medicine and Dentistry of New Jersey, Newark, New Jersey

References 

  1. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513
  2. Tannock IF, deWit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502
  3. Urakami S, Yoshino T, Kikuno N, Imai SH, Yoneda T, Kishi H, et al. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. Urology. 2005;65:543
  4. Yonemori K, Katsumata N, Uno H, Matsumoto K, Kouno T, Tokunaga S, et al. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast Cancer Res Treat. 2005;89:237
  5. Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol. 2005;56(suppl):47
  6. Mani S, Macapinlac M, Goel S, Verdier-Pinard D, Fojo T, Rothenberg M, et al. The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs. 2004;15:553
  7. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253
  8. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996;56:1253
  9. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003;3:193
  10. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol. 2001;28:3
  11. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs. 2003;14:13
  12. Lennernäs B, Albertsson P, Damber J, Norrby K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. APMIS. 2004;112:201
  13. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423
  14. Heldin CH, Rubin K, Pietras K, Õstman A. High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806
  15. Rakesh J. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58
  16. Polgar O, Bates SE. ABC transporters in the balance: is there a role in multidrug resistance?. Biochem Soc Trans. 2005;33:241
  17. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48
  18. Kamath K, Wilson J, Cabral F, Jordan MA. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem. 2005;280:12902
  19. Lih CJ, Wei W, Cohen SN. Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev. 2006;20:2082
  20. DiPaola RS, Aisner J. Overcoming bcl-2- and p53-mediated resistance in prostate cancer. Semin Oncol. 1999;26:112
  21. Ioffe ML, White E, Nelson DA, Dvorzhinski D, DiPaola RS. Epothilone induced cytotoxicity is dependent on p53 status in prostate cells. Prostate. 2004;61:243
  22. Bergstralh DT, Ting JP. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev. 2006;32:166
  23. DiPaola RS, Patel J, Rafi MM. Targeting apoptosis in prostate cancer. Hematol Oncol Clin North Am. 2001;15:509
  24. Thalasila A, Poplin E, Shih J, Dvorzhinski D, Capanna T, Doyle-Lindrud S, et al. A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies. Cancer Chemother Pharmacol. 2003;52:119
  25. Morris MJ, Cordon-Cardo C, Kelly WK, Slovin SF, Siedlecki K, Regan KP, et al. Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Appl Immunohistochem Mol Morphol. 2005;13:6
  26. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, et al. A phase II, pharmacolinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005;11:3854
  27. Hussein M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Study 9346 (INT-0162). J Clin Oncol. 2006;24:3984
  28. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer. Oncogene. 2006;25:329
  29. Lee JT, Steelman LS, McCubrey JA. Phospatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004;64:8397
  30. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644
  31. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, et al. TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396
  32. Wilson LA, Yamamoto H, Singh G. Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther. 2004;3:823
  33. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem. 2001;276:39359
  34. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9(suppl):3
  35. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992;147:935
  36. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20:3072
  37. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, et al. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer. 2003;97:561
  38. Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003;98:1603
  39. Lin JER, Weinberg VK, Kelly WK, Michaelson MD, Hussain M, Wilding G, et al. Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP). J Clin Oncol. 2006;24:4558
  40. Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, et al. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer. 2005;4:86
  41. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006;106:58
  42. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, et al. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer. 2006;5:144
  43. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst. 2006;98:783
  44. Mathew P, Thall PF, Johnson MM, Oh WK, Meluch AA, Morris MJ, et al. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer and bone metastases. J Clin Oncol. 2006;24:4562
  45. Sternberg CN. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int. 2005;96:990
  46. Rowinsky EK, Calvo E. Novel agents that target tubulin and related elements. Semin Oncol. 2006;33:421
  47. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review (Old wine in a new bottle?). Ann Oncol. 2006;17:735
  48. Pellegrini F, Budman DR. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Investig. 2005;23:264
  49. Warner SL, Gray PJ, VonHoff DD. Tubulin-associated drug targets: aurora kinases, polo-like kinases, and others. Semin Oncol. 2006;33:436
  50. Attard G, Greystoke A, Kaye S, DeBono J. Update on tubulin-binding agents. Pathol Biol. 2006;54:72
  51. Attard G, Sarker D, Reid A, Molife R, Parker C, DeBono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer. 2006;95:767

PII: S0022-5347(07)01091-9

doi: 10.1016/j.juro.2007.04.032

The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S36-S41 , September 2007

Article Tools